Opinion|Videos|October 14, 2024
Integrating HER2-Directed Therapies Into Standard Care for NSCLC
Key Takeaways
- HER2-directed therapies offer clinical, operational, and economic benefits in NSCLC management within managed care settings.
- NSCLC patients with HER2 mutations are the primary beneficiaries of HER2-directed therapies, necessitating precise identification.
Panelists discuss how incorporating HER2-directed therapies into NSCLC management strategies within managed care settings impacts clinical outcomes, operational processes, and economic considerations, while emphasizing the importance of identifying and selecting patient populations most likely to benefit from these targeted treatments.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Examine the clinical, operational, and economic implications of incorporating HER2-directed therapies into NSCLC management strategies within managed care settings.
- Which NSCLC patient populations are most likely to benefit from HER2-directed therapies and how should clinicians approach patient selection?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
2
In Its 50th Year, ESMO Comes to Berlin, a City Transformed
3
Physical Activity, Vaccination May Protect Against Long COVID
4
mRNA COVID-19 Vaccines Not Associated With Major Congenital Malformations During Pregnancy
5
